ProvayBlue® (methylene blue) injection is now available in a new 10mL single-dose vial for the treatment of pediatric and adult patients with acquired methemoglobinemia.

The new presentation is available in a box of five 10mL single-dose vials; each vial contains 50mg of methylene blue. ProvayBlue is also available in a box of five 10mL single-dose ampules; each ampule contains 50mL of methylene blue.

“We are pleased that our continued partnership with Provepharm provides the opportunity to expand our line of ProvayBlue products to better meet the needs of providers and patients,” stated Joann Gioia, Vice President and CCO at American Regent, Inc. 

Due to the risk of hemolytic anemia, ProvayBlue is contraindicated for use in patients with severe hypersensitivity reactions to methylene blue or any other thiazine dye, and in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) 

ProvayBlue carries a Boxed Warning associated with a risk of serious or fatal serotonin syndrome when used in combination with serotonergic drugs. Patients should avoid concomitant use of ProvayBlue with selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine inhibitors.

As for safety, the most common adverse reactions (incidence greater than or equal to 10%) for ProvayBlue are pain in extremity, chromaturia, dysgeusia, feeling hot, dizziness, hyperhidrosis, nausea, skin discoloration and headache.

Reference

American Regent launches a new vial presentation. News release. American Regent, Inc. Accessed June 30, 2022. https://www.prnewswire.com/news-releases/american-regent-launches-a-new-vial-presentation-301578994.html